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Abstract 
Bone  marrow  infiltration  by  granulomas
rarely presents with cytopenias and is usually
a result of atypical infections, lymphomas, or
sarcoidosis. Drugs are also an important but
often overlooked causal agent of bone marrow
granulomas.  Although  rare,  amiodarone  has
been associated with bone marrow granuloma
formation.  This  case  report  describes  a  73-
year-old  male  who  presented  with  pancyto  -
penia  during  a  preoperative  evaluation.
Amiodarone therapy was suspected to be the
causal agent after diagnostic evaluation and
exclusion of other causes. After cessation of
amiodarone, the patient’s pancytopenia gradu-
ally resolved over a period of several months.
Our report illustrates an often overlooked yet
important  cause  of  reversible  pancytopenia
owing to suspected amiodarone-induced bone
marrow granuloma formation, and guides clin  -
icians in an expected timeline for blood count
improvement after cessation of this drug.
Introduction
Multifocal bone marrow granulomas result
in pancytopenia by disrupting normal hemato  -
poiesis. Granulomas form by an aggregation of
activated  macrophages  that  undergo  a  mor-
phological  transformation  into  epithelial-like
cells. Granulomas may result from a chronic
inflammatory response incited by persistent or
non-degradable  antigens.1 Identification  of
bone  marrow  granulomas  is  significant
because they are usually a result of a limited
number  of  conditions  including  malignant
lymphomas,  sarcoidosis,  and  atypical  infec-
tions. Additional rarer causes include autoim-
mune disorders such as rheumatoid arthritis,
systemic  lupus  erythematosus,  and  other
malignancies.2-5 A variety of drugs have been
reported to cause bone marrow granulomas,
including  procainamide,  sulfonamide,  and
ibuprofen.6 More  recently,  amiodarone  has
been implicated as a potential cause of bone
marrow granulomas and variable cytopenias,
but rarely pancytopenia.7
Case Report 
A 73-year-old man with severely symptom  -
atic ischemic and valvular cardiomyopathy was
found to have moderately severe pancytopenia
(white  blood  cells,  2.4¥109/L;  absolute  neu-
trophils, 1.39¥109/L; platelets, 65¥109/L; hemo-
globin, 9.8 g/dL with a normal MCV) during a
preoperative evaluation, prior to planned tri-
cuspid valve replacement surgery. The physical
examination  was  consistent  with  tricuspid
valve regurgitation, but notably splenomegaly
and lymphadenopathy were absent. A peripher-
al  blood  smear  confirmed  thrombocytopenia
but was otherwise unremarkable. A bone mar-
row biopsy was performed to clarify the etiolo-
gy of the pancytopenia prior to surgical inter-
vention. The bone marrow biopsy revealed nor-
mal  trilineage  hematopoeisis.  Cytogenetics
and  flow  cytometry  were  likewise  normal.
Surprisingly,  multiple  small  non-caseating
granulomas were present (Figure 1). Special
stains,  cultures,  and  serological  testing  for
associated infectious causes of bone marrow
granulomas,  including  mycobacterial,  fungal
(Aspergillus, Cryptococcus, Histoplasmosis,
Sporothrix, Coccidioides,  Blastomyces),  aero-
bic  and  anaerobic  bacteria  (particularly
Brucellosis and Q-fever), were negative. There
was no clinical evidence for a viral infection
such  as  HIV,  Epstein-Barr  virus,  or
cytomegalovirus, nor for an autoimmune dis-
order such as rheumatoid arthritis or systemic
lupus  erythematosus.  Inflammatory  markers
including  sedimentation  rate  and  C-reactive
protein were both normal. Computed tomogra-
phy of the chest and angiotensin converting
enzyme levels were also unremarkable.
A  review  of  our  patient’s  history  revealed
that  amiodarone  had  been  started  several
years earlier for ventricular tachyarrhythmias,
and mild cytopenias had been noted several
months after initiation of this drug. Careful
review of all other medications failed to reveal
an  obvious  temporal  association  with  his
cytopenias. As such, amiodarone was thought
to be a potential causal agent for the bone mar-
row  granuloma  formation  and  pancytopenia,
and was discontinued.
Within  six  weeks  after  stopping  amio-
darone, with no other medication changes, our
patient’s blood counts improved significantly.
He then underwent successful tricuspid valve
replacement  without  postoperative  complica-
tions related to cytopenias, despite the initia-
tion of warfarin anticoagulation. At the four
month follow-up, our patient’s complete blood
count returned to near normal levels (white
blood  cells,  4.2¥109/L;  absolute  neutrophils,
2.36¥109/L;  platelets,  106¥109/L;  hemoglobin,
12.8 g/dL; Table 1) and he remained asymp  -
tomatic at the last outpatient follow-up. 
Discussion
Amiodarone is a commonly prescribed class
III antiarrhythmic medication that increasing-
ly has been recognized in sporadic case reports
as a potential cause of bone marrow granu  -
lomas.7-13 In several reports, amiodarone was
not  stopped  because  the  treating  physicians
determined  that  the  cardiac  benefits  out-
weighed the potential hematologic risks.9,11,12
Boutros  et  al.8 and  Moran  and  Manoharan10
observed an improvement in cytopenias that
paralleled a partial or complete resolution of
bone  marrow  granulomas  by  three  to  eight
months  after  cessation  of  amiodarone.
Mohamed  et  al.9 reported  a  patient  with
leukopenia  and  thrombocytopenia  that
improved by six months after discontinuation
of amiodarone. Similarly, our patient’s hemo-
globin, white blood cells, and platelets began to
increase at six weeks after cessation of this
drug and all three cell lines reached near nor-
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mal levels by four months. Close follow-up and
regular blood count monitoring allowed us to
define  the  expected  temporal  association
between  amiodarone  cessation  and  blood
count recovery (Table 1). The gradual improve-
ment  observed  in  both  our  patient’s  blood
counts and previous published reports is con-
sistent with the exceptionally long half-life of
amiodarone.14 Although a repeat bone marrow
biopsy  after  its  discontinuation  would  offer
definitive proof, this was not done as it was not
clinically  indicated.  Similarly  re-exposure  to
the drug to illicit a relapse was not ethically
justifiable. Never  theless, our patient’s clinical
evolution  suggests  an  association  between
amiodarone, bone marrow granuloma forma-
tion, and resultant pancytopenia.
Conclusions
Our case implicates amiodarone as a cause
of bone marrow granulomas with associated
pancytopenia, and helps guide clinicians in an
expected  time  course  for  improvement  after
drug cessation. Although reversible, the long
half-life of amiodarone did result in a protract-
ed  duration  of  our  patient’s  pancytopenia.
Early  recognition  and  diagnosis  might  limit
the severity of the associated cytopenias, and
mitigate the subsequent bleeding and infec-
tious complications, and potentially reduce the
need for transfusions. Amiodarone should be
included  in  the  differential  diagnosis  of
patients who present with bone marrow granu  -
lomas and secondary cytopenias, and pancy-
topenia  should  be  added  as  an  additional
reversible  side  effect  of  this  commonly  pre-
scribed antiarrhythmic drug.
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Table 1. Timeline of complete blood count recovery following cessation of amiodarone.
Weeks after cessation Hg* (g/dL) WBC°(¥109/L) Platelets (¥109/L)
0 weeks 9.8 2.5 69
6 weeks 10.8 3.0 86
11 weeks 11.6 3.3 97
16 weeks 12.8 4.2 106
*Hg, hemoglobin; °WBC, white blood cell.
Figure  1.  Non-caseating  granulomas  on
bone  marrow  biopsy  (hematoxylin  and
eosin stain; magnification: 400X).